Key Points
- CEO Eric Venker sold 200,000 Roivant Sciences shares at an average price of $36.62, generating $7.324 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan and reduced his direct ownership by 11.12% to about 1.6 million shares.
- Roivant shares opened at $35.72, with a market capitalization of approximately $25.8 billion, while the company reported a quarterly loss of $0.26 per share and $1.44 million in revenue.
- Analyst sentiment remains broadly positive: 10 analysts rate the stock Buy and the consensus target price is $45.64, although one analyst rates it Sell and institutional investors own 64.76% of outstanding shares.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $36.62, for a total transaction of $7,324,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,599,154 shares in the company, valued at approximately $58,561,019.48. The trade was a 11.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Venker also recently made the following trade(s):
- On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.77, for a total transaction of $7,154,000.00.
- On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00.
Roivant Sciences Trading Up 0.6%
Shares of NASDAQ ROIV opened at $35.72 on Friday. The firm has a fifty day simple moving average of $36.58 and a two-hundred day simple moving average of $32.57. Roivant Sciences Ltd. has a 12 month low of $15.25 and a 12 month high of $42.50. The firm has a market capitalization of $25.80 billion, a PE ratio of -67.40 and a beta of 1.10.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to analysts' expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -2 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on ROIV. Stifel Nicolaus began coverage on shares of Roivant Sciences in a research note on Wednesday, September 16th. They issued a "buy" rating and a $51.00 target price on the stock. TD Cowen upped their target price on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, September 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Jefferies Financial Group boosted their price objective on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. Finally, HC Wainwright raised their target price on shares of Roivant Sciences from $41.00 to $47.00 and gave the stock a "buy" rating in a report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Roivant Sciences has an average rating of "Moderate Buy" and a consensus target price of $45.64.
Get Our Latest Analysis on ROIV
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Parallel Advisors LLC boosted its stake in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after acquiring an additional 520 shares during the period. Bessemer Group Inc. lifted its holdings in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after purchasing an additional 441 shares in the last quarter. Root Financial Partners LLC lifted its holdings in Roivant Sciences by 187.9% in the 1st quarter. Root Financial Partners LLC now owns 2,914 shares of the company's stock worth $81,000 after purchasing an additional 1,902 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Roivant Sciences by 76.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,433 shares of the company's stock worth $123,000 after purchasing an additional 1,916 shares during the period. Finally, Fifth Third Bancorp boosted its stake in Roivant Sciences by 8.7% in the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock worth $130,000 after purchasing an additional 376 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.
Roivant's research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
